News

search close

Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market

Read more

Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression

Read more

Relmada Therapeutics to Present at LD Micro Invitational Conference in Los Angeles

Read more

Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting

Read more

Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results

Read more

Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations

Read more

Relmada Therapeutics to Present at Biotech Showcase 2019

Read more

Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017

Read more

Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels

Read more

Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder

Read more